Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

Lancet. 1992 Jan 11;339(8785):71-85.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / therapy*
  • Chemotherapy, Adjuvant
  • Cisplatin / therapeutic use
  • Female
  • Fluorouracil / therapeutic use
  • Global Health
  • Humans
  • Immunotherapy*
  • Methotrexate / therapeutic use
  • Middle Aged
  • Multicenter Studies as Topic
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / prevention & control*
  • Ovariectomy
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Tamoxifen / therapeutic use
  • Time Factors
  • Treatment Outcome

Substances

  • Tamoxifen
  • Cisplatin
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CMF protocol